Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors-Reference-Cited by-同舟云学术

Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

Published:2020-07-15 Issue:8 Volume:11 Page:1548-1554
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Pu Qinglin^ORCID,Zhang Hongjun^ORCID,Guo Liangqin,Cheng Mangeng,Doty Amy C.,Ferguson Heidi^ORCID,Fradera Xavier^ORCID,Lesburg Charles A.,McGowan Meredeth A.,Miller J. Richard,Geda Prasanthi,Song Xuelei,Otte Karin,Sciammetta Nunzio,Solban Nicolas,Yu Wensheng¹^ORCID,Sloman David L.,Zhou Hua,Lammens Alfred²,Neumann Lars²,Bennett David Jonathan,Pasternak Alexander,Han Yongxin

Affiliation:

1. External Discovery Chemistry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

2. Proteros Biostructures GmbH, Bunsenstr. 7a, D-82152 Planegg, Martinsried, Germany

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.0c00195

Reference30 articles.

1. Harnessing the Power of the Immune System to Target Cancer

2. Cancer immunotherapy: harnessing the immune system to battle cancer